About the Company To d a y ’ s A b d i I b r a h i m Company Profile* www.abdiibrahim.com.tr Shareholders: Barut and Esirtgen Families Abdi Ibrahim Tower: Istanbul, Turkey Production and R&D: Esenyurt, Istanbul Turnover: $853 million Export: $27 million Production Capacity: 350 million boxes Product Range: 53% original pharmaceuticals 47% generic pharmaceuticals Licensors: ~ 30 international companies Employees: ~ 3,300 * As of December 2011 About the Company Vision To be a well-respected, widely preferred global player that strives to grow more rapidly than the respective pharmaceutical market Mission To produce and supply healthcare products through a pioneering and innovative approach, for the benefit of medicine and humanity www.abdiibrahim.com.tr About the Company A Journey of 100 Years to the Summit Istanbul Istanbul Algeria The business started in 1912 with a small pharmacy in Istanbul In 1940, the number of drugs produced at the Abdi Ibrahim Laboratory reached 80 www.abdiibrahim.com.tr The foundations of the production facilities were laid in 1994 Portfolio: 150 brands, more than 250 products, close to 30 licensors, exports to more than 20 countries In 1999, international expansion started with the first venture into Algeria EU GMP approved manufacturing facility and first accredited R&D Industry Leader for 9 Years Turnover — Consolidated Turnover (Millon $) Turnover — Consolidated Turnover (TL) 896 1,424 853 849 1,343 805 761 1,158 1,160 1,035 614 575 878 774 400 577 335 186 495 217 329 160 201 110 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 * As of December 2011 www.abdiibrahim.com.tr Industry Leader Domestic Sales Development Turnover Development (TL) Turnover Development ($ mio) 865 1,379 1,297 786 826 819 735 1,114 1,121 1,011 603 559 861 753 387 560 327 484 322 197 185 212 157 110 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Domestic sales (contract man. included) www.abdiibrahim.com.tr 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Domestic sales turnover (contract man. included) * As of December 2011 Industry Leader Market Share Leader in Turkey Market Share — Units (2011) ABDI 9.3% Bayer 6.8% Bilim 6.2% Eastpharma 5.6% Ulugay 4.9% Sanofi Novartis Market Share — $ Turnover (2011) 4.7% 3.8% ABDI 7.9% Novartis 6.0% Bilim 5.1% Pfizer 4.8% Eastpharma 4.1% Glaxo-SmithKline 3.8% Sanofi 3.7% Glaxo-SmithKline 3.4% Bayer 3.4% Pfizer 3.3% Astra Zeneca 3.3% Santa Farma 3.2% Sanovel www.abdiibrahim.com.tr 2.9% Ref. IMS Industry Leader Export Development 31 30 27 25 19 16 13 11 8 5 3 1 2000 2001 2002 2003 2004 2005 2006 US $ million www.abdiibrahim.com.tr 2007 2008 2009 2010 2011 Industry Leader $274 Million Investment (1990-2011) 48.4 Before 2000 225.2 www.abdiibrahim.com.tr Fixed Assets After 2000 $ million Industry Leader Success is a Team Game The Largest Sales and Marketing Team in Turkey (2010 - 2011) Number of employees ~ 3300* 2,100 550 400 150 * Includes Abdica, Reformed and International Markets www.abdiibrahim.com.tr Manufacturing Plant Logistic Center Production Capacity: Production Area: Employees: Closed Area: Total Palette Capacity: 350 million boxes 25,000 sqm > 500 • Adhering to global standards • cGMP and cGLP certifications • ISO 14001 Environmental Management System Certification • OHSAS 18001 Work Safety Certification • EU GMP approved facility • “Energy-Efficient Industrial Facility” Award in 2007 • Modern, efficient and environment-friendly technology • 2D Matrix Codes technology in the production line automation system 22,000 sq m 14,500 • With an investment of $35 million, Abdi Ibrahim Logistic Center is equipped with the latest state-of-the-art equipment allowing for faster transport and greater performance with fully automation system First Accredited R&D Center in Turkey Total Closed Area: Laboratory: Pilot Production Area: Offices: Storage Area: Employees: 13,600 sq m 2,000 sq m 900 sq m 450 sq m 350 sq m > 150 High level of success in bioequivalence studies CTD files for Turkey and Europe Accelerated development process for equivalent products Development of value-added products Global Reach Abdi Ibrahim Global Export to more than 20 Countries Production of Original and Generic Pharmaceuticals Licensing www.abdiibrahim.com.tr Marketing and Registration Global Licencors www.abdiibrahim.com.tr List of Countries Aİ Operates Own Markets Third Party Countries (Operation through own organization/reps) Algeria Kazakhstan Azerbaijan Georgia Ukraine Iraq Moldova (Operation through distributor) www.abdiibrahim.com.tr Afghanistan Vietnam Yemen Albania Libya Hong Kong Jordan Russia Turkmenistan Kosovo Lebanon Germany France UK Belgium Netherlands Canada Uganda, Sudan, Mauritius List of Countries Aİ Operates Outlicensing Countries ( As of 2012) • • • • • • • • • • • • www.abdiibrahim.com.tr Brazil Venezuella South Africa Tunusia Morocco Austria Spain Switzerland Hungary Bulgaria Croatia GCC 100th Year Rational Medicine Usage Campaign Undertaking responsibility on the “Rational Medicine Use” campaign initiated by the World Health Organization for the first time in 1985 and applied by the T.R. Ministry of Health since 1992, Abdi İbrahim aims to contribute to preventing the effects of irrational medicine use on the public health and economy. Transmitting its messages to the public with the collaboration of doctors and pharmacists via visual and printed materials in health institutions within the context of the Rational Medicine Use Campaign, Abdi İbrahim also aims to contribute to preventing the waste of resources and establishment of a healthier society by reaching a broader audience via TV ads, radio spots and magazine advertisements. Van Gogh Alive The Turkish pharmaceutical industry leader, Abdi İbrahim, will be celebrating its 100th anniversary with an impressive exhibit never before experienced, in which the works of one of the most famous artists in the world, Vincent Van Gogh, will be presented in a whole new format. This exhibit, where the famous works of Vincent Van Gogh come to life at enormous scale, immersing the audience in a vibrant symphony of light, color & sound reflects Abdi İbrahim’s 100 year vision, by blending art, science and technology with an innovative approach.